...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

"Wonder what Pfizer thoughts r on this"

Got ta pondering the above a tad more.

Is this Zen trying to create some competitive tension? Maybe there's one or two more BP's as well sniffing around & Don figures that this route is a decent gamble? Either way he continues to fill his pockets so I like it in the sense he's not under as much pressure to tak or make some half baked deal??On the other hand if no BP bites we the shareholder have a long long ride ahead of us unless he gets us on a exchange & we start trading in 6-8 months???

Share
New Message
Please login to post a reply